tiprankstipranks
Advertisement
Advertisement

AZN Stock Latest News

AstraZeneca, Daiichi Sankyo’s Datroway approved in EU
The FlyAstraZeneca, Daiichi Sankyo’s Datroway approved in EU
19h ago
AZN
AstraZeneca Wins EU Nod for Datroway, Strengthening TNBC Oncology Portfolio
PremiumCompany Announcements
AstraZeneca Wins EU Nod for Datroway, Strengthening TNBC Oncology Portfolio
23h ago
AZN
Why I’m Bullish on IONQ after the Selloff
PremiumMarket News
Why I’m Bullish on IONQ after the Selloff
2d ago
AZN
ENRD
AstraZeneca Shuts Down China NASH Registry: What It Means for AZN Investors
PremiumCompany Announcements
AstraZeneca Shuts Down China NASH Registry: What It Means for AZN Investors
3d ago
AZN
AstraZeneca Earnings Call: Oncology Strength Amid Setbacks
PremiumCompany Announcements
AstraZeneca Earnings Call: Oncology Strength Amid Setbacks
3d ago
AZN
AstraZeneca’s AZD2389 Liver Fibrosis Study Reaches Key Early Milestone
PremiumCompany AnnouncementsAstraZeneca’s AZD2389 Liver Fibrosis Study Reaches Key Early Milestone
5d ago
AZN
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
Premium
The Fly
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
5d ago
F
GM
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
Premium
The Fly
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
5d ago
AZN
OMER
Omeros up 11% to $10.89 after AstraZeneca study failure
PremiumThe Fly
Omeros up 11% to $10.89 after AstraZeneca study failure
5d ago
AZN
OMER
Morning Movers: Ensign Group surges following second quarter results
PremiumThe Fly
Morning Movers: Ensign Group surges following second quarter results
5d ago
AMR
AZN
AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint
PremiumThe Fly
AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint
5d ago
AZN
AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint
PremiumThe Fly
AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint
5d ago
AZN
AstraZeneca reports Sone-Ve improved survival in gastric cancers
PremiumThe FlyAstraZeneca reports Sone-Ve improved survival in gastric cancers
5d ago
AZN
AstraZeneca: Buy Rating Reiterated as Strong Q2, Robust Pipeline Support Unchanged 16,500 GBp Price Target
Premium
Ratings
AstraZeneca: Buy Rating Reiterated as Strong Q2, Robust Pipeline Support Unchanged 16,500 GBp Price Target
5d ago
AZN
AstraZeneca reaffirms FY26 revenue, core EPS guidance
Premium
The Fly
AstraZeneca reaffirms FY26 revenue, core EPS guidance
5d ago
AZN
AstraZeneca ‘on track’ to deliver ambition of $80B in revenue in 2030
PremiumThe Fly
AstraZeneca ‘on track’ to deliver ambition of $80B in revenue in 2030
5d ago
AZN
AstraZeneca reports Q2 core EPS $2.63, up 18% at CER
PremiumThe Fly
AstraZeneca reports Q2 core EPS $2.63, up 18% at CER
5d ago
AZN
AstraZeneca raises interim dividend to $1.06 per share
PremiumThe Fly
AstraZeneca raises interim dividend to $1.06 per share
5d ago
AZN
AstraZeneca’s Alexion Reports Mixed Ultomiris Trial Results in HSCT‑TMA, Advances Paediatric Filings
PremiumCompany Announcements
AstraZeneca’s Alexion Reports Mixed Ultomiris Trial Results in HSCT‑TMA, Advances Paediatric Filings
5d ago
AZN
AstraZeneca’s Sone-Ve delivers pivotal survival benefit in CLDN18.2-positive gastric cancer
PremiumCompany AnnouncementsAstraZeneca’s Sone-Ve delivers pivotal survival benefit in CLDN18.2-positive gastric cancer
5d ago
AZN
AstraZeneca Delivers Solid H1 Growth and Bolsters Pipeline with Strategic Deals
Premium
Company Announcements
AstraZeneca Delivers Solid H1 Growth and Bolsters Pipeline with Strategic Deals
5d ago
AZN
MIRANDA Trial Completion: AstraZeneca’s Tozorakimab Targets High-Risk COPD Market
Premium
Company Announcements
MIRANDA Trial Completion: AstraZeneca’s Tozorakimab Targets High-Risk COPD Market
8d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >